Get started
Work

Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.

Year: 2021
Type: conference-abstract
DOI: 10.1200/jco.2021.39.15_suppl.7041
Authors: Jacqueline Suen Garcia, Andrew Wei, Uma Borate, Chun Yew Fong, Maria R. Baer, Daniel Nowak, Pierre Peterlin, Joseph G. Jurcic, Meagan Jacoby, Uwe Platzbecker, Olatoyosi Odenike, Ilona Cunningham, Ying Zhou, David Hoffman, Kiran Naqvi, Steve Kye, Guillermo Garcia-Manero
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, The Alfred Hospital, Monash University, Oregon Health & Science University, OHSU Knight Cancer Institute, Austin Health, Olivia Newton-John Cancer Research Institute, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Heidelberg University, Medizinische Fakultät Mannheim, Centre Hospitalier Universitaire de Nantes, Columbia University Irving Medical Center, Barnes-Jewish Hospital, Washington University in St. Louis, University Hospital Leipzig, University of Chicago Medical Center, The University of Sydney, Concord Repatriation General Hospital, AbbVie (United States), Genentech, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
Funder: AbbVie
OpenAlex ID: W3166566542
Cites:
Cited by:
Related to: 10